Analysts See $-0.13 EPS for Fennec Pharmaceuticals Inc. (FRX)

August 9, 2018 - By Lisa Delgado

Fennec Pharmaceuticals Inc. (TSE:FRX) Logo

Analysts expect Fennec Pharmaceuticals Inc. (TSE:FRX) to report $-0.13 EPS on August, 10.They anticipate $0.02 EPS change or 13.33 % from last quarter’s $-0.15 EPS. After having $-0.11 EPS previously, Fennec Pharmaceuticals Inc.’s analysts see 18.18 % EPS growth. The stock decreased 2.28% or $0.29 during the last trading session, reaching $12.44. About 2,018 shares traded. Fennec Pharmaceuticals Inc. (TSE:FRX) has 0.00% since August 9, 2017 and is . It has underperformed by 12.57% the S&P500.

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. The company has market cap of $233.33 million. The Company’s lead product candidate is the Sodium Thiosulfate, a water soluble thiol compound that acts as a chemical reducing agent, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. It currently has negative earnings. The firm was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.